ALBUMIN (HUMAN) 25% SOLUTION 25 %
ALBUMIN (HUMAN) : 25 % · DIN 00427659 · BAXTER AG
Health Canada status: CANCELLED POST MARKET
What is ALBUMIN (HUMAN) 25% SOLUTION?
ALBUMIN (HUMAN) 25% SOLUTION 25 % contains ALBUMIN (HUMAN) : 25 %. It is listed in the Health Canada Drug Product Database under DIN 00427659, held by BAXTER AG, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 14-Mar-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00427659 |
|---|---|
| Brand name | ALBUMIN (HUMAN) 25% SOLUTION |
| Generic / active ingredient | ALBUMIN (HUMAN) : 25 % |
| Manufacturer | BAXTER AG |
| Strength | 25 % |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B05AA01 ALBUMIN |
| AHFS class | 16:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 14-Mar-2008 |
| Original market date | 1989-10-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05AA01 ALBUMIN. 5 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALBUMIN (HUMAN) 25% SOLUTION USP | 25 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02223708 |
| ALBUMIN (HUMAN) 5% SOLUTION, USP | 5 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02223694 |
| ALBUREX - 25 | 25 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02274663 |
| ALBUREX - 5 | 5 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02274655 |
| PLASBUMIN-5 | 50 MG | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02189100 |
| ALBUMIN (HUMAN) 5% SOLUTION | 5 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | DIN 00427675 |
| ALBUMINAR-25 | 25 G / 100 ML | SOLUTION | ZLB BEHRING LLC | CANCELLED POST MARKET | DIN 00624608 |
| ALBUTEIN 25% SOLN USP | 250 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | DIN 00779571 |
| ALBUTEIN 5% SOLN USP | 50 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | DIN 00779563 |
| BUMINATE 25% | 25 % | SOLUTION | BAXTER HEALTHCARE CORPORATION | CANCELLED POST MARKET | DIN 00118303 |
Who else supplies ALBUMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALBUMIN appears in 91 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.